Treatment and complications in elderly stage III colon cancer patients in the Netherlands

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 974-979

  Hoeben, K W J ^a   van Steenbergen, L N ^b   van de Wouw, A J ^a   Rutten, H J ^c   van Spronsen, D J ^d,e   Janssen Heijnen, M L G ^a,b  

^a VIECURI MEDICAL CENTER   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant chemotherapy; Colon cancer; Elderly; Recurrence; Survival; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ABDOMINAL DISEASE; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; DEATH; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM; URINARY TRACT INFECTION; WOUND INFECTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMORBIDITY; DRUG TOXICITY; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM STAGING; NETHERLANDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84875592258     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds576     Document Type: Article

References (36)

1. Moertel CG, Fleming TR, Macdonald JS et al.. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-326.
2. Sargent D, Sobrero A, Grothey A et al.. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-877.
3. Chau I, Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev 2002; 28: 223-236.
4. Andre T, Boni C, Mounedji-Boudiaf L et al.. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
5. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20: 3992-3998.
6. Zuckerman IH, Rapp T, Onukwugha E et al.. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc 2009; 57: 1403-1410.
7. Goldberg RM, Tabah-Fisch I, Bleiberg H et al.. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
8. Jackson McCleary NA, Meyerhardt J, Green E et al.. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol 2009; 27: 4010.
9. van Steenbergen LN, Elferink MA, Krijnen P et al.. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. Ann Oncol 2010; 21: 2206-2212.
10. Van Steenbergen LN, Lemmens VE, Rutten HJ et al.. Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in the Netherlands. Ann Oncol 2012; 23: 2805-2811.
11. Ananda S, Field KM, Kosmider S et al.. Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. J Clin Oncol 2008; 26: 4516-4517; author reply 4517-4518.
12. van Steenbergen LN, Rutten HJ, Creemers GJ et al.. Large age and hospitaldependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann Oncol 2010; 21: 1273-1278.
13. Droz JP, Aapro M, Balducci L. Overcoming challenges associated with chemotherapy treatment in the senior adult population. Crit Rev Oncol Hematol 2008; 68(Suppl 1): S1-S8.
14. Krzyzanowska MK, Regan MM, Powell M et al.. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg 2009; 208: 202-209.
15. Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet 2000; 356: 968-974.
16. Elferink MA, van Steenbergen LN, Krijnen P et al.. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer 2010; 46: 1421-1429.
17. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 1995; 31A: 1955-1959.
18. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86: 1766-1770.
19. Piccirillo JF, Tierney RM, Costas I et al.. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447.
20. Etzioni DA, El-Khoueiry AB, Beart RW, Jr. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008; 113: 3279-3289.
21. Jessup JM, Stewart A, Greene FL et al.. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711.
22. Schrag D, Cramer LD, Bach PB et al.. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-857.
23. Papamichael D, Audisio R, Horiot JC et al.. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009; 20: 5-16.
24. Potosky AL, Harlan LC, Kaplan RS et al.. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20: 1192-1202.
25. Sundararajan V, Mitra N, Jacobson JS et al.. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with nodepositive colon cancer. Ann Intern Med 2002; 136: 349-357.
26. Sargent DJ, Goldberg RM, Jacobson SD et al.. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
27. Kobayashi H, Mochizuki H, Sugihara K et al.. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 2007; 141: 67-75.
28. O'Connell MJ, Campbell ME, Goldberg RM et al.. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 2008; 26: 2336-2341.
29. Hsiao FY, Mullins CD, Onukwugha E et al.. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a 'real world' analysis using surveillance, epidemiology, and end results-medicare data. J Am Geriatr Soc 2011; 59: 1717-1723.
30. Sanoff HK, Carpenter WR, Martin CF et al.. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104: 211-227.
31. Sanoff HK, Carpenter WR, Sturmer T et al.. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624-2634.
32. Dekker JW, van den Broek CB, Bastiaannet E et al.. Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. Ann Surg Oncol 2011; 18: 1533-1539.
33. Bastiaannet E, Portielje JE, van de Velde CJ et al.. Lack of survival gain for elderly women with breast cancer. Oncologist 2011; 16: 415-423.
34. John V, Mashru S, Lichtman S. Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging 2003; 20: 737-759.
35. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003; 1: 18-24.
36. Hu CY, Chan W, Delclos GP et al.. Adjuvant Chemotherapy and Risk of Gastrointestinal, Hematologic, and Cardiac Toxicities in Elderly Patients With Stage III Colon Cancer. Am J Clin Oncol 2012; 3: 228-236.